Provided by Tiger Fintech (Singapore) Pte. Ltd.

Boston Scientific

102.98
-0.0850-0.08%
Volume:2.57M
Turnover:265.37M
Market Cap:152.35B
PE:75.14
High:103.49
Open:103.15
Low:102.43
Close:103.07
Loading ...

Acotec Scientific Holdings Ltd. Receives PRC National Medical Products Administration Approval for AcoArt Verbena® Paclitaxel-Coated Balloon Catheter

Reuters
·
Yesterday

Boston Scientific Corp. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
03 Jun

Goldman Sachs Adjusts Price Target on Boston Scientific to $119 From $117, Maintains Buy Rating

MT Newswires Live
·
02 Jun

Boston Scientific Director Makes a Lucrative Stock Sale

TIPRANKS
·
31 May

Director Edward J. Ludwig Reports Disposal of Boston Scientific Corporation Common Shares

Reuters
·
31 May

Boston Scientific Unveils AI Breakthrough: Predicting Heart Failure Weeks in Advance with HeartLogic™ System

Reuters
·
30 May

Acotec Scientific Holdings Ltd. Secures PRC National Medical Products Administration Approval for E-Peridge® Peripheral Scoring Balloon Dilatation Catheter

Reuters
·
29 May

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Axsome Therapeutics (AXSM)

TIPRANKS
·
29 May

J.P. Morgan Reaffirms Their Buy Rating on Boston Scientific (BSX)

TIPRANKS
·
29 May

Boston Scientific Price Target Maintained With a $115.00/Share by Needham

Dow Jones
·
29 May

Boston Scientific Acurate TAVR discontinuation a positive, says Barclays

TIPRANKS
·
29 May

Boston Scientific's Farapulse, Watchman to Drive Upside After Acurate's Discontinuation, Needham Says

MT Newswires Live
·
28 May

Boston Scientific Shares Down 1.3% After Co to Stop Heart Device Sales Amid Regulatory Challenges

THOMSON REUTERS
·
28 May

Boston Scientific’s Strategic Shift and Resilient Outlook: A Buy Rating with 17.7% Expected Return

TIPRANKS
·
28 May

Boston Scientific’s Strategic Shift and Growth Potential: A Buy Rating Amid Product Discontinuation and Promising Innovations

TIPRANKS
·
28 May

Boston Scientific Shares Down 2% Premarket After Co to Discontinue Heart Device Amid Regulatory Challenges

THOMSON REUTERS
·
28 May

Boston Scientific to not seek US approval for heart device amid regulatory challenges

Reuters
·
28 May

Boston Scientific Corp: Not Reaffirming Its Q2 and FY 2025 Gaap EPS Guidance Issued on April 23

THOMSON REUTERS
·
28 May

Boston Scientific Corp: No Longer Pursuing U.S. FDA Approval for Acurate or Approval in Other Geographies

THOMSON REUTERS
·
28 May

Boston Scientific Corp: Discontinuing Worldwide Sales of Acurate Neo2™ & Acurate Prime™ Aortic Valve Systems

THOMSON REUTERS
·
28 May